Pharmaceutical Lipid-Based Excipients Market Size, Share, and Trends 2025 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology  

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pharmaceutical Lipid-Based Excipients Market 

5.1. COVID-19 Landscape: Pharmaceutical Lipid-Based Excipients Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pharmaceutical Lipid-Based Excipients Market, By Excipient Type

8.1. Pharmaceutical Lipid-Based Excipients Market Revenue and Volume, by Excipient Type

8.1.1. Phospholipids

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Glycerides / Mono-, Di-, Tri-glyceride

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Sorbitan & Polyethylene Glycol (PEG) Esters

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Sterols & Phytosterols

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Other Lipid-Based Excipients

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global Pharmaceutical Lipid-Based Excipients Market, By Formulation Type

9.1. Pharmaceutical Lipid-Based Excipients Market Revenue and Volume, by Formulation Type

9.1.1. Solid Dosage Form

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Liquid Dosage Forms

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Semisolids / Topicals

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Injectables / Parenteral Lipid-Based Formulation

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Other Specialized Formulations

9.1.5.1. Market Revenue and Volume Forecast

Chapter 10. Global Pharmaceutical Lipid-Based Excipients Market, By Application / Therapeutic Area 

10.1. Pharmaceutical Lipid-Based Excipients Market Revenue and Volume, by Application / Therapeutic Area

10.1.1. Oncology

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. CNS Disorder

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Cardiovascular Diseases

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Infectious Diseases

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Gastrointestinal & Hepatic Disorder

10.1.5.1. Market Revenue and Volume Forecast

10.1.6. Vaccines / Biologics

10.1.6.1. Market Revenue and Volume Forecast

10.1.7. Other Therapeutic

10.1.7.1. Market Revenue and Volume Forecast

Chapter 11. Global Pharmaceutical Lipid-Based Excipients Market, By End-User / Customer Segment

11.1. Pharmaceutical Lipid-Based Excipients Market Revenue and Volume, by End-User / Customer Segment

11.1.1. Pharmaceutical Manufacturers

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Biopharmaceutical Companie

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Contract Development & Manufacturing Organizations (CDMOs)

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Research Institutes / Academia

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Pharmaceutical Lipid-Based Excipients Market, By Patient Demographics / Age Group

12.1. Pharmaceutical Lipid-Based Excipients Market Revenue and Volume, by Patient Demographics / Age Group

12.1.1. Adults (18–64)

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Elderly (65+)

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Adolescents (13–17)

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Pediatric (0–12)

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global Pharmaceutical Lipid-Based Excipients Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Excipient Type

13.1.2. Market Revenue and Volume Forecast, by Formulation Type

13.1.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.1.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.1.5. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Excipient Type

13.1.6.2. Market Revenue and Volume Forecast, by Formulation Type

13.1.6.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.1.6.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.1.6.5. Market Revenue and Volume Forecast, by Patient Demographics / Age Group  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Excipient Type

13.1.7.2. Market Revenue and Volume Forecast, by Formulation Type

13.1.7.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.1.7.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.1.7.5. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Excipient Type

13.2.2. Market Revenue and Volume Forecast, by Formulation Type

13.2.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.2.4. Market Revenue and Volume Forecast, by End-User / Customer Segment  

13.2.5. Market Revenue and Volume Forecast, by Patient Demographics / Age Group  

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Excipient Type

13.2.6.2. Market Revenue and Volume Forecast, by Formulation Type

13.2.6.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.2.7. Market Revenue and Volume Forecast, by End-User / Customer Segment  

13.2.8. Market Revenue and Volume Forecast, by Patient Demographics / Age Group  

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Excipient Type

13.2.9.2. Market Revenue and Volume Forecast, by Formulation Type

13.2.9.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.2.10. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.2.11. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Excipient Type

13.2.12.2. Market Revenue and Volume Forecast, by Formulation Type

13.2.12.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.2.12.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.2.13. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Excipient Type

13.2.14.2. Market Revenue and Volume Forecast, by Formulation Type

13.2.14.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.2.14.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.2.15. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Excipient Type

13.3.2. Market Revenue and Volume Forecast, by Formulation Type

13.3.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.3.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.3.5. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Excipient Type

13.3.6.2. Market Revenue and Volume Forecast, by Formulation Type

13.3.6.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.3.6.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.3.7. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Excipient Type

13.3.8.2. Market Revenue and Volume Forecast, by Formulation Type

13.3.8.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.3.8.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.3.9. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Excipient Type

13.3.10.2. Market Revenue and Volume Forecast, by Formulation Type

13.3.10.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.3.10.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.3.10.5. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Excipient Type

13.3.11.2. Market Revenue and Volume Forecast, by Formulation Type

13.3.11.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.3.11.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.3.11.5. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Excipient Type

13.4.2. Market Revenue and Volume Forecast, by Formulation Type

13.4.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.4.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.4.5. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Excipient Type

13.4.6.2. Market Revenue and Volume Forecast, by Formulation Type

13.4.6.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.4.6.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.4.7. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Excipient Type

13.4.8.2. Market Revenue and Volume Forecast, by Formulation Type

13.4.8.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.4.8.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.4.9. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Excipient Type

13.4.10.2. Market Revenue and Volume Forecast, by Formulation Type

13.4.10.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.4.10.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.4.10.5. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Excipient Type

13.4.11.2. Market Revenue and Volume Forecast, by Formulation Type

13.4.11.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.4.11.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.4.11.5. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Excipient Type

13.5.2. Market Revenue and Volume Forecast, by Formulation Type

13.5.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.5.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.5.5. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Excipient Type

13.5.6.2. Market Revenue and Volume Forecast, by Formulation Type

13.5.6.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.5.6.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.5.7. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Excipient Type

13.5.8.2. Market Revenue and Volume Forecast, by Formulation Type

13.5.8.3. Market Revenue and Volume Forecast, by Application / Therapeutic Area

13.5.8.4. Market Revenue and Volume Forecast, by End-User / Customer Segment

13.5.8.5. Market Revenue and Volume Forecast, by Patient Demographics / Age Group

Chapter 14. Company Profiles

14.1. ABITEC Corporation

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. BASF SE

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Chemaris S.A.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. CordenPharma

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Croda International plc

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Evonik Industries AG

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. IOI Loders Croklaan

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. IOI Oleo GmbH

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Lipoid GmbH

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Merck KGaA

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms